Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

XeriSol glucagon

Recombinant protein · Agonist of glucagon receptor (GCGR)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is XeriSol glucagon?

XeriSol glucagon is a stable, soluble liquid formulation of recombinant glucagon that can be injected or delivered through an insulin pump. It is being studied for use in artificial pancreas systems to treat type 1 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Recombinant protein
Targets
glucagon receptor (GCGR)
Mechanism
Agonist of glucagon receptor (GCGR)
Therapy area
Endocrine
In trials of
XERS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03424044 Phase 1 Type1diabetes Completed XERS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type1diabetes

Other drugs acting on GCGR

Glucagon FDA approved Volagidemab Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.